

**QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE SECOND QUARTER ENDED 30 JUNE 2008.**

**THE FIGURES HAVE NOT BEEN AUDITED.**

**I. CONDENSED CONSOLIDATED INCOME STATEMENT**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter <b>30/06/2008</b> RM'000	Preceding year corresponding quarter <b>30/06/2007</b> RM'000	Six months to <b>30/06/2008</b> RM'000	Six months to <b>30/06/2007</b> RM'000
1. (a) <b>Revenue</b>	<b>353,465</b>	<b>300,231</b>	<b>663,115</b>	<b>556,466</b>
(b) Cost of sales	(295,744)	(256,315)	(544,511)	(475,290)
(c) Gross profit	57,721	43,916	118,604	81,176
(d) Other income	547	115	834	570
(e) Expenses	(36,471)	(30,075)	(68,632)	(54,847)
(f) Finance costs	(1,160)	(2,224)	(3,016)	(4,665)
(g) Share of results of associate	451	449	672	177
(h) <b>Profit before income tax</b>	<b>21,088</b>	<b>12,181</b>	<b>48,462</b>	<b>22,411</b>
(i) Income tax	(7,631)	(4,964)	(16,023)	(8,701)
(j) <b>Profit for the period</b>	<b>13,457</b>	<b>7,217</b>	<b>32,439</b>	<b>13,710</b>
Attributable to:				
(k) Equity holders of the Company	13,107	6,640	31,652	12,709
(l) Minority interest	350	577	787	1,001
	<b>13,457</b>	<b>7,217</b>	<b>32,439</b>	<b>13,710</b>
2. <b>Earnings per share attributable to equity holders of the Company :-</b>				
(a) Basic	<b>12.25 sen</b>	<b>6.21 sen</b>	<b>29.59 sen</b>	<b>11.88 sen</b>
(b) Fully diluted	- *	-*	- *	-*

\*The fully diluted earnings per share is not shown as the effect is anti-dilutive.

The condensed Consolidated Income Statement should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2007.

## II. CONDENSED CONSOLIDATED BALANCE SHEET

	<b>Unaudited As at end of current quarter 30/06/2008</b>	<b>Audited As at preceding financial year end 31/12/2007</b>
	RM'000	RM'000
<b>ASSETS</b>		
1. Non-current assets		
Property, plant and equipment	245,444	241,013
Prepaid lease payments	21,378	21,431
Investments in associated companies	7,114	6,441
Goodwill	31,620	31,620
Other intangible assets	1,052	2,368
Deferred tax assets	2,910	2,297
	<b>309,518</b>	<b>305,170</b>
2. Current assets		
Inventories	178,188	182,130
Receivables	389,577	289,845
Amount due from intermediate holding company	20	18
Amounts due from related companies	5,767	13,698
Amounts due from associated companies	-	1,087
Tax recoverable	1,916	2,796
Fixed deposits	1,980	8
Cash and bank balances	24,049	56,132
	<b>601,497</b>	<b>545,714</b>
3. Non-current assets held for sale	<b>33,838</b>	<b>33,965</b>
Total assets	<b>944,853</b>	<b>884,849</b>

**II. CONDENSED CONSOLIDATED BALANCE SHEET (CONT'D)**

	<b>Unaudited As at end of current quarter 30/06/2008</b>	<b>Audited As at preceding financial year end 31/12/2007</b>
	RM'000	RM'000
<b>EQUITY AND LIABILITIES</b>		
4. Equity attributable to equity holders of the Company		
Share capital	106,963	106,963
Reserves		
Share premium	22,410	22,410
Other reserves	159	(253)
Retained earnings	232,950	220,551
	362,482	349,671
5. Minority interest	13,576	12,789
Total equity	376,058	362,460
6. Non-current liabilities		
Long term borrowings	49,123	58,486
Deferred tax liabilities	3,784	3,767
	52,907	62,253
7. Current liabilities		
Payables	348,563	286,561
Amounts due to related companies	2,398	2,561
Amounts due to associated companies	1,837	716
Tax payable	9,831	3,842
Dividend payable	19,259	7
Short term borrowings	88,133	133,449
Current portion of long term borrowings	45,867	33,000
	515,888	460,136
Total liabilities	568,795	522,389
Total equity and liabilities	944,853	884,849
8. <b>Net assets per share attributable to ordinary equity holders of the Company</b>	<b>RM3.39</b>	<b>RM3.27</b>

The condensed Consolidated Balance Sheet should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2007.

**III. CONDENSED CONSOLIDATED CASH FLOW STATEMENT**

	<b>Unaudited Six months to 30/06/2008 RM'000</b>	<b>Unaudited Six months to 30/06/2007 RM'000</b>
<b>Operating activities</b>		
Cash receipts from customers and related parties	583,046	506,408
Cash payments to suppliers	(481,871)	(420,656)
Cash payments to employees and for expenses	(68,615)	(54,611)
Cash generated from operations	<u>32,560</u>	<u>31,141</u>
Interest paid	(1,801)	(2,934)
Profit on Murabahah Commercial Paper paid	(565)	(548)
Income taxes paid	(11,488)	(3,632)
Interest received	17	73
<b>Net cash generated from operating activities</b>	<u>18,723</u>	<u>24,100</u>
<b>Investing activities</b>		
Proceeds from disposal of property, plant and equipment	137	65
Purchase of property, plant and equipment	(9,062)	(13,355)
<b>Net cash used in investing activities</b>	<u>(8,925)</u>	<u>(13,290)</u>
<b>Financing activities</b>		
Repayments of short term borrowings	(33,398)	(20,871)
Redemption of Murabahah Commercial Paper	-	(10,000)
Repayment of term loan	(4,500)	(8,100)
Term loan interest paid	(1,008)	(1,660)
Profit on Murabahah Medium Term Notes paid	(985)	(1,248)
Fixed deposits pledged	(3)	(9)
<b>Net cash used in financing activities</b>	<u>(39,894)</u>	<u>(41,888)</u>
<b>Net change in cash and cash equivalents</b>	<u>(30,096)</u>	<u>(31,078)</u>
Currency translation differences	(18)	(154)
Net cash and cash equivalents as at beginning of financial period	56,132	68,573
<b>Net cash and cash equivalents as at end of financial period</b> (a)	<u>26,018</u>	<u>37,341</u>

**III. CONDENSED CONSOLIDATED CASH FLOW STATEMENT (CONT'D)**

	<b>Unaudited As at 30/06/2008 RM'000</b>	<b>Unaudited As at 30/06/2007 RM'000</b>
(a) <b>Cash and cash equivalents comprise the following amounts:</b>		
Cash and bank balances	24,049	37,341
Fixed deposits	1,980	970
	<b>26,029</b>	<b>38,311</b>
Less: Fixed deposits pledged to banks	(11)	(970)
Cash and cash equivalents	<b>26,018</b>	<b>37,341</b>

The condensed Consolidated Cash Flow Statement should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2007.

**IV. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY**

← Equity attributable to equity holders of the Company →

	Share capital RM'000	Share premium RM'000	Other reserves RM'000	Exchange reserves RM'000	Retained earnings RM'000	Total RM'000	Minority interest RM'000	Total equity RM'000
<b>Six months to 30 June 2008 (unaudited)</b>								
Balance as at 1 January 2008	106,963	22,410	3,428	(3,681)	220,551	349,671	12,789	362,460
Currency translation differences, representing expenses recognised directly in equity	-	-	-	68	-	68	-	68
Profit for the period	-	-	-	-	31,652	31,652	787	32,439
Total recognised income and expense for the period	-	-	-	68	31,652	31,720	787	32,507
2007 final 18.0% tax exempt dividend	-	-	-	-	(19,253)	(19,253)	-	(19,253)
Employee equity scheme: - options granted	-	-	344	-	-	344	-	344
Balance as at 30 June 2008	<u>106,963</u>	<u>22,410</u>	<u>3,772</u>	<u>(3,613)</u>	<u>232,950</u>	<u>362,482</u>	<u>13,576</u>	<u>376,058</u>

**IV. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY**

← Equity attributable to equity holders of the Company →

	Share capital RM'000	Share premium RM'000	Other reserves RM'000	Exchange reserves RM'000	Retained earnings RM'000	Total RM'000	Minority interest RM'000	Total equity RM'000
<b>Six months to 30 June 2007 (unaudited)</b>								
Balance as at 1 January 2007	106,963	22,410	1,310	(958)	186,515	316,240	11,151	327,391
Currency translation differences, representing expenses recognised directly in equity	-	-	-	(621)	-	(621)	-	(621)
Profit for the period	-	-	-	-	12,709	12,709	1,001	13,710
Total recognised income and expense for the period	-	-	-	(621)	12,709	12,088	1,001	13,089
Share-based payment	-	-	1,151	-	-	1,151	-	1,151
2006 final 15.0 % tax exempt dividend	-	-	-	-	(16,044)	(16,044)	-	(16,044)
Balance as at 30 June 2007	<u>106,963</u>	<u>22,410</u>	<u>2,461</u>	<u>(1,579)</u>	<u>183,180</u>	<u>313,435</u>	<u>12,152</u>	<u>325,587</u>

The condensed Consolidated Statement of Changes in Total Equity should be read in conjunction with the Annual Financial Statements for the year ended 31 December 2007.

## V. NOTES TO THE CONDENSED FINANCIAL STATEMENTS

The notes to the condensed Financial Statements should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2007.

### 1. Accounting policies and methods of computation

The quarterly consolidated financial statements have been prepared by applying accounting policies and methods of computation consistent with those used in the preparation of the most recent audited financial statements of the Group and are in accordance with FRS 134, Interim Financial Reporting and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") except for the mandatory adoption of the following revised Financial Reporting Standards ("FRS") effective for the financial period beginning on 1 January 2008:

FRS 107	Cash Flow Statements
FRS 112	Income Taxes
FRS 118	Revenue
FRS 120	Accounting for Government Grants and Disclosure of Government Assistance
Amendments to FRS 121	The Effects of Changes in Foreign Exchange Rates - Net Investment in a Foreign Operations
FRS 134	Interim Financial Reporting
FRS 137	Provisions, Contingent Liabilities and Contingent Assets

The adoptions of the above FRSs do not have any significant financial impact to the Group.

### 2. Audit report in respect of the 2007 financial statements

The audit report on the Group's financial statements for the financial year ended 31 December 2007 was not qualified.

### 3. Seasonal or cyclical factors

The Group's operations are not subject to any significant seasonal or cyclical factors.

### 4. Unusual items due to their nature, size or incidence

There were no items affecting assets, liabilities, equity, net income, or cash flows that were unusual because of their nature, size or incidence in the current financial period ended 30 June 2008.

### 5. Material changes in estimates used

There were no other changes in estimates of amounts reported in prior interim period of the current financial period or prior financial years that have a material effect in the current period.

### 6. Debt and equity securities

The Group did not undertake any other issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares for the current financial period ended 30 June 2008.

### 7. Dividend

No interim ordinary dividend has been declared for the financial period ended 30 June 2008 (2007: nil).

A final tax exempt dividend of 18.0% (2006: 15.0%) on 106,963,188 (2006: 106,963,188) ordinary shares of RM1.00 each in respect of the previous financial year amounting to RM19,253,374 (2006: RM16,044,478 ) was approved by shareholders on 22 May 2008 and paid on 2 July 2008.



8. **Segment information for the current financial period**

Segment information for the current financial period to 30 June 2008 is as follows:

	Pharmaceutical manufacturing RM'000	Pharmaceutical trading, marketing and distribution RM'000	Medical products and services RM'000	Other operations RM'000	Eliminations RM'000	Group RM'000
<b>Revenue</b>						
External revenue	4,633	642,660	15,822	-	-	663,115
Inter-segment revenue	117,791	658	-	26,893	(145,342)	-
Total revenue	122,424	643,318	15,822	26,893	(145,342)	663,115
<b>Results</b>						
Segment results	21,050	31,220	(111)	22,493	(16,505)	58,147
Unallocated corporate expenses						(7,700)
Profit from operations						50,447
Interest expense	-	(1,795)	(11)	(2,957)	1,747	(3,016)
Interest income	-	359	-	1,747	(1,747)	359
Share of results of associate						672
Profit before income tax						48,462
Income tax						(16,023)
<b>Profit for the period</b>						<b>32,439</b>
Attributable to:						
Equity holders of the Company						31,652
Minority interest						787
						<u>32,439</u>

9. **Non current assets held for sale**

Non current assets held for sale are:

- (a) an intention by the Group to dispose certain property, plant and equipment with a net book value of RM33,532,866 in one of its subsidiary company to a third party. The Directors were made aware that the third party which had initially agreed to purchase the property, plant and equipment had withdrawn its intention. However, the Directors are still committed to its plan and are aggressively sourcing a potential buyer; and
- (b) a property, plant and equipment to be disposed with a net book value of RM305,000 held by a subsidiary company of the Group, namely Pharmaniaga Trading (M) Sdn. Bhd. which is currently undergoing liquidation.

## 10. Changes in the composition of the Group

There were no significant changes in the composition of the Group for the current quarter and financial period including business combinations, acquisitions or disposals of subsidiaries and long term investments, restructuring or discontinued operations except as disclosed below:

- (a) the liquidation of the two dormant subsidiary companies of the Group, namely Pharmaniaga Medisystem Sdn. Bhd. and Pharmaniaga Diagnostics Sdn. Bhd., and an associated company, Rumpun Lagenda Sdn. Bhd. has been completed, and one dormant subsidiary company of the Group, namely Pharmaniaga Trading (M) Sdn. Bhd. is in progress; and
- (b) on 2 July 2008, the Company had acquired 2 ordinary shares of RM1.00 each fully paid representing 100% equity interest in Pharmaniaga Biovention Sdn. Bhd. of which its application for bionexus status is currently in progress; and
- (c) the Jiangsu Province Wuxi Intermediate People's Court, upon application by Wuxi Worldbest Treeful Pharma Pharmaceutical Co. Ltd. ("WWTPP"), has ruled on 10 July 2007 to accept the bankruptcy application of WWTPP in accordance with the law. On 16 July 2007, the Court further appointed Wuxi Jin Shun Economic Consulting Co. Ltd. as the Bankruptcy Administrator for WWTPP to take control over WWTPP. Pharmaniaga Pegasus (Seychelles) Co. Ltd. ("Pharmaniaga Pegasus") has then appointed a legal representative and an arbitrator for the participation in the Creditors Meeting and bankruptcy proceeding respectively. The date for the Creditors Meeting has not been fixed, pending litigation from local parties. However Pharmaniaga Pegasus claims right amount due to them has been affirmed by the Bankruptcy Administrator.

## 11. Contingent liabilities

There are no changes in the contingent liabilities as at the date of this announcement since the preceding financial year ended 31 December 2007 except as disclosed below:

	As at 01/01/2008	Increase	Decrease	As at 30/06/2008
	RM'000	RM'000	RM'000	RM'000
Bank performance and reimbursement bonds for concession business undertaken by a subsidiary company	45,000	-	-	45,000
Bank guarantees for projects and utilities undertaken by subsidiary companies	25,116	-	(9,003)	16,113
<b>Total</b>	<b>70,116</b>	<b>-</b>	<b>(9,003)</b>	<b>61,113</b>

## 12. Capital commitments

Authorised capital expenditures for the purchase of property, plant and equipment not provided for in the condensed consolidated financial statements were as follows:

	<b>As at 30/06/2008 RM'000</b>
Authorised and contracted for:	
- acquisition of property, plant and equipment	9,054
Authorised but not contracted for:	
- acquisition of property, plant and equipment	<u>1,944</u>

13. **Income tax**

	Individual Quarter		Cumulative Quarter	
	Current year quarter	Preceding year corresponding quarter	Six months to	Six months to
	30/06/2008	30/06/2007	30/06/2008	30/06/2007
	RM'000	RM'000	RM'000	RM'000
Malaysian taxation				
- Current taxation	7,275	4,503	15,543	7,812
- Deferred taxation	23	-	(316)	-
Sub-total	<u>7,298</u>	<u>4,503</u>	<u>15,227</u>	<u>7,812</u>
Foreign taxation				
- Current taxation	548	434	1,077	775
- Deferred taxation	(215)	27	(281)	114
Sub-total	<u>333</u>	<u>461</u>	<u>796</u>	<u>889</u>
Grand Total	<u>7,631</u>	<u>4,964</u>	<u>16,023</u>	<u>8,701</u>

The effective tax rate for the current quarter and year to date are higher than statutory tax rate as a result of non-allowable expenses and losses in a subsidiary which has yet to commence operation coupled with certain plant and equipment in one of its manufacturing subsidiary which do not qualify for reinvestment allowance.

14. **Disposal of unquoted investments and/or properties**

There were no disposals of unquoted investments and/or properties in the current period.

15a) **Acquisitions and disposals of quoted securities**

There were no acquisitions and disposals of quoted securities in the current period.

15b) **Investments in quoted securities**

There were no investments in quoted securities as at 30 June 2008.

16. **Status of corporate proposals announced but not completed as at the date of this announcement**

There are no corporate proposals announced but not completed as at the date of this announcement except for:

- (a) on 5 February 2008, the Company entered into a Memorandum of Understanding ("MOU") with Visor Holding LLP ("Visor") of the Republic of Kazakhstan to collaborate and jointly participate in the Republic of Kazakhstan's healthcare industry. The negotiation with Visor on the terms of the collaboration has ended due to disagreement on certain commercial term. On 30 July 2008, the Company and Visor mutually terminated the MOU; and
- (b) on 15 February 2008, the Company announced that it has been notified by UEM Group Berhad ("UEM Group") through CIMB Investment Bank Berhad that UEM World Berhad ("UEM World") has on the same day announced a proposed non-renounceable restricted offer for sale of all of its ordinary share in its listed subsidiaries which includes the Company to the shareholders of UEM World ("Proposed ROS"). UEM Group has given an undertaking to UEM World to subscribe for its entitlement under the Proposed ROS as well as the shares in the Company which are not taken up or applied for by other shareholders (including under the excess application process) under the Proposed ROS. Upon the Proposed ROS becoming unconditional, in accordance with Part II of the Malaysian Code on Take-Overs and Mergers, 1998 ("Code"), UEM Group will be obliged to extend a mandatory take-over offer for the remaining voting shares in the Company that UEM Group does not already own ("Pharmaniaga MGO").

17. **Borrowings and debt securities**

Details of Group borrowings and debt securities as at 30 June 2008 are as follows:

	Long term borrowings			Short term borrowings		
	Secured	Unsecured	Total	Secured	Unsecured	Total
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<b><u>Debt securities</u></b>						
Domestic						
- Murabahah Commercial Paper	-	-	-	-	29,708	29,708
- Murabahah Medium Term Notes	-	29,811	29,811	-	15,000	15,000
<b><u>Other borrowings</u></b>						
Domestic						
- Bankers acceptance	-	-	-	-	58,356	58,356
- Term loan	18,900	-	18,900	18,450	-	18,450
Foreign						
Indonesia Rupiah						
- Term loan	185	-	185	12,275	-	12,275
- Time loan	-	-	-	69	-	69
- Hire purchase	227	-	227	142	-	142
<b>TOTAL</b>	<b>19,312</b>	<b>29,811</b>	<b>49,123</b>	<b>30,936</b>	<b>103,064</b>	<b>134,000</b>

18. **Off Balance Sheet financial instruments**

There are no financial instruments with off-balance sheet risks as at the date of this announcement.

19. **Material litigation**

Since the preceding financial year ended 31 December 2007, there are no changes in material litigation as at the date of this announcement except for the following:

**(a) Demand by Siemens Financial Services GmbH ("Siemens") for USD12.0 million**

As at the date of this announcement, the Company confirms that no civil suit on the Company and its subsidiaries, Pharmaniaga Logistics Sdn. Bhd. ("PLSB") and Safire Pharmaceuticals (M) Sdn. Bhd. ("Safire") has been filed by Siemens.

The Board of Directors of the Company upon consultation with the solicitors, is of the opinion that the positions of both PLSB and Safire are defensible.

## 19. Material litigation (Continued)

### **(b) Danaharta Urus Sdn. Bhd. vs Safri bin Nawawi (“Safri”) and Hamimah Binti Idruss (“Hamimah”) (by original action)** **Safri bin Nawawi & Anor vs Danaharta Urus Sdn. Bhd. and 6 others (action by counterclaim)**

The Company announced on 18 January 2005, that Safri bin Nawawi and Hamimah binti Idruss, former directors of Safire, on 28 December 2004 have each commenced an action by way of Counterclaim against the Company in the legal suit originally filed by Danaharta Urus Sdn. Bhd. against them. The Company and Safire are named 4<sup>th</sup> Defendant and 3<sup>rd</sup> Defendant respectively in both Actions by Counterclaim and were served with the court papers on 11 January 2005. The Company had filed its Memorandum of Appearance in Court on 14 January 2005 and 18 January 2005 in respect of the Counterclaim.

The Company and Safire have both filed their respective defense to the Action by Counterclaim on 31 January 2005. The Company has further filed an application to strike out the Counterclaim on 3 March 2005.

The decision on the Company's application to strike out the Counterclaim by Safri and Hamimah is pending the disposal of the appeals by Safri and Hamimah on the various interlocutory applications. The matter has been fixed for hearing on 10 November 2008.

The Board of Directors of the Company upon consultation with the solicitors, is of the opinion that the positions of both the Company and Safire are defensible.

## 20. Comparison between the current quarter and the immediate preceding quarter

The Group's revenue for the current quarter of RM353.5 million compared to RM309.7 million in the immediate preceding quarter showed a growth of 14.1%. The growth was spurred by the increase in concession and non concession sales to government hospitals by 15.1% and 23.7% respectively. The performance of its Indonesian operation, PT Millennium Pharmacon International Tbk also registered a growth of 11.2%.

The Group's profit before taxation of RM21.1 million for the second quarter ended 30 June 2008 was 23.0% lower than its immediate preceding quarter ended 30 March 2008 (RM27.4 million). The contraction was mainly due to lower margin recorded from concession sales to government hospitals and private sector sales as a result of higher raw material prices incurred in the current quarter.

## 21. Review of performance for the current quarter and period

The Group's revenue performance for the second quarter ended 30 June 2008 grew by 17.7% over that of the same quarter last year. The growth was mainly contributed from all market sectors, most notably from Ministry of Health, Institutions, General Health Care, Medical Equipment Unit and Contract Manufacturing market segments. In addition, its Indonesian subsidiary performance has also improved by 10.7%, contributing to approximately 21.6% to the Group's revenue.

The Group's profit before taxation (“PBT”) for the second quarter ended 30 June 2008 rose by 73.1% over the same quarter last year. The current quarter PBT was mainly boosted by higher revenue and improved margins.

Similarly, the Group's year to date revenue grew by 19.2% compared to the same period last year. The growth was mainly spurred by increase in sales to government hospitals and private sector by 18.5% and 20.7% respectively.

The Group's year to date profit before taxation increased by 116.2% over that of the same period last year following growth in revenue and improved margins in practically all market segments.

## 22. Prospects for 2008

As previously announced, the Group has set its main headline Key Performance Indicators (“KPI”) of Revenue Growth and Return on Equity of 20% and 18% respectively. The Management is cognizant of rising energy and raw materials costs and has put in motion aggressive marketing strategies, process improvements to enhance product quality and efficiency and cost containment in order to achieve its KPI.

## 23. Profit forecast

No commentary is made on any variance between actual profit from forecast profit, as it does not apply to the Group.

## 24. Earnings per share

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter <b>30/06/2008</b> RM'000	Preceding year corresponding quarter <b>30/06/2007</b> RM'000	Six months to <b>30/06/2008</b> RM'000	Six months to <b>30/06/2007</b> RM'000
<b>(a) Basic earnings per share</b>				
Profit attributable to equity holders of the Company	13,107	6,640	31,652	12,709
Weighted average number of ordinary shares in issue ('000)	106,963	106,963	106,963	106,963
<b>Basic earnings per share</b>	<b><u>12.25 sen</u></b>	<b><u>6.21 sen</u></b>	<b><u>29.59 sen</u></b>	<b><u>11.88 sen</u></b>

The computations of diluted earnings per share for both the current period and preceding period ended 30 June 2007 were not calculated as the potential ordinary shares are anti-dilutive coupled with the average market prices of the ordinary shares are lower than the ESOS price.

## 25. Voluntary disclosure on Economic Profit ("EP") Statement

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter <b>30/06/2008</b> RM'000	Preceding year corresponding quarter <b>30/06/2007</b> RM'000	Six months to <b>30/06/2008</b> RM'000	Six months to <b>30/06/2007</b> RM'000
<b>Economic Profit</b>	<b>10,113</b>	<b>3,562</b>	<b>24,215</b>	<b>6,083</b>

### Explanatory notes

The EP statement is as prescribed under the GLC Transformation program, and is disclosed on a voluntary basis. EP is a measure of value created by a business during a single period reflecting how much return a business makes over its cost of capital.

The EP performance for the period to date recorded RM24.2 million as compared to RM6.1 million last year. The underlying factor for the increase is in line with the better operational performance registered by the Group.

**By Order of the Board**

Kuala Lumpur  
14 August 2008

**WONG LEE LOO (MAICSA 7001219)**  
**NORHANA BINTI OTHMAN (LS0008547)**  
Joint Secretaries